Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Multidrug Resistant Bacteria Market Through 2029?

The market size for multidrug-resistant bacteria has observed robust growth in the past few years. The market is projected to expand from $12.61 billion in 2024 to $13.27 billion in 2025, recording a compound annual growth rate (CAGR) of 5.2%. Factors like the antibiotic resistance crisis, progress in drug discovery, regulatory incentives, and public health initiatives have largely contributed to the growth in the historical period.

The market size for multidrug resistant bacteria is projected to expand significantly in the coming years, reaching “$17.28 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%. The predicted growth in the forecasted period can be traced back to antibiotic stewardship programs, worldwide resistance spread, phage therapy, and alternative treatments with both public and private investment. Key trends anticipated during this period include precision medicine for infectious diseases, combination therapies, ongoing surveillance and monitoring, and global collaboration.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13044&type=smp

What Market Forces Are Driving The Multidrug Resistant Bacteria Sector In 2025 And Beyond?

The rise in infectious diseases is anticipated to fuel the expansion of the multidrug-resistant bacteria market in the future. These diseases are caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are intrinsically linked with infectious diseases due to their capacity to trigger infections that are tough to cure with regular antibiotics. Such bacteria have evolved to resist numerous antibiotics, thereby reducing their vulnerability to the medicines typically used against bacterial infections. As per an article by the Centers for Disease Control and Prevention, a public health agency in the US, in November 2023, the count of tuberculosis patients in the USA saw an increase from 8,320 in 2022 to 9,615 in 2023, indicating an increase of 1,295 cases. Thus, the escalating prevalence of infectious diseases is set to steer the growth of the multidrug-resistant bacteria market.

The multidrug resistant bacteria market covered in this report is segmented –

1) By Disease: Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Acute Bacterial Skin And Skin Structure Infections, Hospital Acquired Bacterial Pneumonia, Acquired Bacterial Pneumonia, Other Diseases

2) By Drug Class: Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies, Other Drug Classes

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Urinary Tract Infection: Cystitis, Pyelonephritis

2) By Intra-Abdominal Infections: Appendicitis, Peritonitis

3) By Blood Stream Infections: Bacteremia, Sepsis

4) By Clostridium Difficile Infections: Mild CDI, Severe CDI

5) By Acute Bacterial Skin And Skin Structure Infections: Cellulitis, Abscesses

6) By Hospital Acquired Bacterial Pneumonia: Ventilator-Associated Pneumonia, Hospital-Acquired Pneumonia

7) By Acquired Bacterial Pneumonia: Community-Acquired Pneumonia, Aspiration Pneumonia

By Other Diseases: Bone and Joint Infections, Endocarditis

What Future Market Trends Are Projected For The Multidrug Resistant Bacteria Industry?

Major firms in the multidrug-resistant bacteria market are focusing their efforts on the creation of innovative drugs and securing necessary approval to cater to a novel consumer segment. Securing approval for drugs that combat multidrug-resistant bacteria is crucial in halting the progression of antibiotic resistance. For example, in May 2023, US biotech firm Entasis Therapeutics Inc. was granted FDA approval for Xacduor, a combination antibiotic designed to tackle hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) originating from acinetobacter baumannii. This bacteria can be particularly difficult to manage. Xacduor is made up of ceftolozane, a cephalosporin antibiotic, and tedizolid phosphate, a new drug in the oxazolidinone class. The drug offers an alternative for patients with Acinetobacter baumannii who have shown no positive response to other forms of treatment. It is administered as an injection, coupling the antibiotic beta-lactam sulbactam with broad-spectrum durlobactam, a beta-lactamase inhibitor; this combination effectively lowers acinetobacter resistance and boosts the efficacy of the antibiotic.

Which Firms Are Considered Leaders In The Multidrug Resistant Bacteria Market Space?

Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

What Role Do Regional Policies And Investments Play In Multidrug Resistant Bacteria Market Expansion?

North America was the largest region in the multidrug-resistant bacteria market in 2024. The regions covered in multidrug-resistant bacteria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13044&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model